Publications in collaboration with researchers from Centre Hospitalier de l’Université de Montréal (63)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  3. Correction: Lymph node metastasis in level IIb in oropharyngeal squamous cell carcinoma: a multicentric, longitudinal, retrospective analysis (European Archives of Oto-Rhino-Laryngology, (2023), 280, 2, (869-876), 10.1007/s00405-022-07647-6)

    European Archives of Oto-Rhino-Laryngology

  4. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  5. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  6. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  7. Influence of Otolaryngological Subspecialties on Perception of Transoral Robotic Surgery: An International YO-IFOS Survey

    Journal of Personalized Medicine, Vol. 13, Núm. 12

  8. Lymph node metastasis in level IIb in oropharyngeal squamous cell carcinoma: a multicentric, longitudinal, retrospective analysis

    European Archives of Oto-Rhino-Laryngology, Vol. 280, Núm. 2, pp. 869-876

  9. Non-Squamous Cell Carcinoma of the Larynx: A State-of-the-Art Review

    Journal of Personalized Medicine, Vol. 13, Núm. 7

  10. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644